Alfonso G Zulueta Eli Lilly & CO (LLY) insider trading activity

Alfonso G Zulueta is SVP & President, Lilly Int'l of ELI LILLY & Co. Currently has a direct ownership of 56,947 shares of LLY, which is worth approximately $50.5 Million. The most recent transaction as insider was on Feb 08, 2021, when has been sold 29,037 shares (Common Stock) at a price of $205.77 per share, resulting in proceeds of $5,974,944. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 56.9K

0% 3M change

0% 12M change

Total Value Held $50.5 Million

Alfonso G Zulueta Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 08 2021	BUY Grant, award, or other acquisition	$5,974,944 $205.77 p/Share	29,037 Added 33.77%	56,947 Common Stock
Feb 01 2021	SELL Payment of exercise price or tax liability	$1,557,695 $207.97 p/Share	7,490 Reduced 21.16%	27,910 Common Stock
Feb 01 2021	BUY Exercise of conversion of derivative security	-	16,754 Added 32.12%	35,400 Common Stock
Jul 09 2020	SELL Open market or private sale	$1,870,000 $170.0 p/Share	11,000 Reduced 37.1%	18,646 Common Stock
Jun 16 2020	SELL Open market or private sale	$2,762,500 $162.5 p/Share	17,000 Reduced 36.44%	29,646 Common Stock
Jun 05 2020	SELL Open market or private sale	$1,500,000 $150.0 p/Share	10,000 Reduced 17.65%	46,646 Common Stock
Feb 11 2020	BUY Grant, award, or other acquisition	-	18,322 Added 24.44%	56,646 Common Stock
Feb 01 2020	SELL Payment of exercise price or tax liability	$1,019,232 $139.64 p/Share	7,299 Reduced 16.0%	38,324 Common Stock
Feb 01 2020	BUY Exercise of conversion of derivative security	-	16,317 Added 26.34%	45,623 Common Stock
Dec 06 2019	SELL Open market or private sale	$540,000 $120.0 p/Share	4,500 Reduced 13.31%	29,306 Common Stock
Sep 20 2019	SELL Open market or private sale	$526,500 $117.0 p/Share	4,500 Reduced 11.75%	33,806 Common Stock
Sep 03 2019	SELL Open market or private sale	$2,201,745 $112.91 p/Share	19,500 Reduced 33.73%	38,306 Common Stock
Apr 12 2019	SELL Open market or private sale	$1,246,500 $124.65 p/Share	10,000 Reduced 14.75%	57,806 Common Stock
Feb 04 2019	BUY Grant, award, or other acquisition	$2,550,488 $120.17 p/Share	21,224 Added 23.84%	67,806 Common Stock
Feb 01 2019	SELL Payment of exercise price or tax liability	$523,069 $119.86 p/Share	4,364 Reduced 8.57%	46,582 Common Stock
Feb 01 2019	BUY Exercise of conversion of derivative security	-	9,722 Added 16.02%	50,946 Common Stock
Jan 31 2019	SELL Open market or private sale	$480,000 $120.0 p/Share	4,000 Reduced 8.84%	41,224 Common Stock
Oct 04 2018	SELL Open market or private sale	$802,480 $114.64 p/Share	7,000 Reduced 13.4%	45,224 Common Stock
Sep 18 2018	SELL Open market or private sale	$321,000 $107.0 p/Share	3,000 Reduced 5.43%	52,224 Common Stock
Sep 17 2018	SELL Open market or private sale	$316,830 $105.61 p/Share	3,000 Reduced 5.15%	55,224 Common Stock
Feb 01 2018	SELL Payment of exercise price or tax liability	$580,983 $81.45 p/Share	7,133 Reduced 10.91%	58,224 Common Stock
Feb 01 2018	BUY Exercise of conversion of derivative security	-	15,993 Added 19.66%	65,357 Common Stock
Jan 29 2018	BUY Grant, award, or other acquisition	$816,082 $87.6 p/Share	9,316 Added 15.88%	49,364 Common Stock
Dec 04 2017	SELL Open market or private sale	$303,752 $86.0 p/Share	3,532 Reduced 8.1%	40,048 Common Stock
Nov 10 2017	SELL Open market or private sale	$167,591 $83.67 p/Share	2,003 Reduced 4.39%	43,580 Common Stock

Also insider at

CTS

CTS CORP Technology

Director

SYNH

Syneos Health, Inc. Healthcare

Director

AMRN

AMARIN CORP PLCUK Healthcare

FLAG

First Light Acquisition Group, Inc. Financial Services

Director

AGZ